Previous reports have shown that interleukin-6 (IL-6) enhances the responsiveness of platelets to thrombin stimulation and has modest thrombocytopoietic effects in vivo. Thrombopoietin 1TPO; mpl ligand) has been shown to have dramatic thrombocytopoietic effects in vivo, but little is known of its capacity to alter platelet function. In this study, a direct comparison of the effects of IL-6 and TPO on platelet function in dogs has been performed, with modest doses of TPO (1 pg/kg/d) chosen to match or moderately exceed the platelet counts achieved with IL-6 (40 pg/kg/d) for 10 days.
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Platelet responsiveness to thrombin stimulation was assessed in TPO-treated, IL-6-treated, and control dogs by flow cytometric measurement of P-selectin expression. On day 5, the dose of thrombin promoting half maximal stimulation (E&) of platelets was not significantly changed in TPOtreated dogs, whereas in IL-6-treated dogs the ECm decreased to 73.1% 2 6.1% (mean * l SD; n = 5) of control values ( P c 0.01). These experiments were performed on both gel-filtered platelets and washed whole blood, indicat-NTERLEUKIN-6 (IL-6), a cytokine with numerous bio-I logical consequences,' shows a variety of effects on the hemostatic mechanism, including inducing a modest elevation in the platelet count in normal and thrombocytopenic animals as well as in human^,"^ an augmentation of plasma fibrin~gen,~ and an enhancement of platelet size and platelet f~nction. 6 .~ These alterations of platelet function may originate at the level of the megakaryocyte, because direct incubation of canine platelets with IL-6 has no effect on the activation capacity of platelets in response to thr~mbin.~ Since IL-6 increases the platelet production rate, 8 it is conceivable that the observed changes in platelet function reflect an increase in young, more hemostatically effective platelets, rather than a specific alteration caused by the cytokine. ' The recently described growth factor thrombopoietin (TPO; mpl ligand), has been shown to have very potent thrombopoietic effects in mice, but little is known about its influence on platelet function.1°-16 Because the elevation in platelet count caused by TPO is almost certainly a result of increased production, the hormone provides an alternative ing that the observed changes in E& were caused by cytokine-mediated alteration of platelets rather than plasma components. Because it has been shown that thiazole orange specifically labels a subpopulation of dog platelets that is less than 24 hours old, the thrombin responsiveness of these young, newly synthesized platelets was determined. The ECso of thiazole orange-positive platelets from IL-6-treated dogs decreased dramatically by day 5 to 46.5% & 13.1% (n = 4) of control values 1P < 0.001), whereas TPOtreated dogs did not significantly change. When TPO was directly incubated with platelets ex vivo, no effects on either thrombin-mediated P-selectin expression or adenosine diphosphate-induced fibrinogen binding were observed. These data show that IL-6 alters platelet function, as measured by reactivity to thrombin, whereas TPO does not. This divergence in function is observed even though TPO is equally, or more, effective at promoting platelet production under these experimental conditions. 0 1996 by The American Society of Hematology. approach in experimental animals to transiently increase the number of young platelets in the circulation. Furthermore, we have recently described a method to identify platelets less than 24 hours old in the dog." With these developments, it is now feasible to directly compare the effects of IL-6 and TPO on platelet reactivity and to ascertain if the IL-6-mediated alterations in platelet function previously described' reflect only an increase in young platelets or perhaps an alteration in platelet reactivity.
MATERIALS AND METHODS

Materials.
Bovine thrombin, prostaglandin E, (PGE,), and bovine serum albumin (BSA) were obtained from Sigma Chemical Co (St Louis, MO). Fluorescein isothiocyanate (FITC) and phycoerythrin-labeled streptavidin (streptavidin-PE) were obtained from Calbiochem (La Jolla, CA). NHS-biotin was obtained from Pierce Chemical Co (Rockford, IL). Caltag Laboratories (South San Francisco, CA) provided the streptavidin-TRI-COLOR, and rabbit antihuman fibrinogen was from Dako Laboratories (Carpinteria, CA). Thiazole orange (TO) was supplied as Retic-COUNT Kit from Becton Dickinson (San Jose, CA). Formalin was obtained from Fisher Scientific (Fairlawn, NJ).
The buffers used were as follows: BSGC, pH 7.3 (buffered saline-glucose-citrate: 129 mmol/L NaCl, 13.6 mmol/L Na? citrate, 11.1 mmol/L glucose, 1.6 mmol/L KHZP04, 8.6 m m o w NaH,PO, [pH, 7.31; ACD (acid citrate dextrose: 38.1 mmom citric acid, 74.8 mmol/L Na7 citrate, 136 mmol/L glucose); and PBS (phosphate buffered saline: 150 mmol/L NaCI, 10 mmol/L NaH,P04 [pH, 7.41).
Recombinant human IL-6 was expressed in Eschericheria coli and purified as previously described.6 Concentration and purity were assessed by the IL-6-responsive B9 cell bioassay'' and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Endotoxin levels were measured using the limulus amebocyte lysate test at Endosafe Inc (Charleston, SC). The specific activity of the purified product was 2 to 5 x IOs U/mg protein and had an endotoxin level of less than 2 U/mg. City, OK) raised against human P-selectin and cross-reacting with the canine counterpart, was used. 2F9 was directly fluoresceinated with FITC and G5 was biotinylated with NHS-biotin using standard techniques. Biotinylated Tab (provided by R. McEver; an IgG, MoAb recognizing human but not dog platelets) was used as an isotype-specific control to set gates for resting versus activated platelets. MoAbs to detect canine fibrinogen were produced by immunizing BalblC mice with purified dog fibrinogen." Antigen was injected bimonthly 3 times into multiple subcutaneous and intraperitoneal sites of Balb/C mice. Serum antifibrinogen titers were determined by enzyme-linked immunosorbent assay (ELISA). Four days after a final injection was administered intravenously, the mice were killed, and the spleen cells were fused in 50% polyethylene glycol-1500 (Sigma) at pH 7.0 to Sp2/0 murine myeloma cells according to standard techniques." Hybrids were identified after hypoxanthine, aminopterin, and thymidine (HAT) selection, expanded, and assayed for antifibrinogen antibody by ELISA. Positive clones were subcloned twice from single cells by limiting dilution. One hybridoma, designated 2B11, was used in these studies.
Animals. Beagles (8 to 13 kg; Hazleton Research Products, Cumberland, VA) were obtained and housed according to the regulations of the Institutional Animal Care and Use Committee (IACUC) of the University of Oklahoma Health Sciences Center (Oklahoma City, OK; accredited by the American Association for Accreditation of Laboratory Animal Care).
Blood samples for baseline determinations were drawn followed by administration of TPO (diluted in 0.15 mol/ L NaCl supplemented with 5% autologous dog plasma) at 1 pg/kg/ d or IL-6 at 40 pg/kg/d in the same diluent buffer, both in a single subcutaneous dose for 10 days (days 0 through 9). Control animals received the diluent buffer on the same schedule.6 Blood samples for analysis of cell counts, fibrinogen assay, quantitation of TO+ platelets, and platelet activation were drawn 2 to 3 times weekly.
Gel filtration was used to deplete platelets of plasma components. For thrombin dose-response studies, 5 mL of blood was drawn into 1/10 vol ACD-A with prostaglandin El (final concentration in blood, 0.5 pmom); for fibrinogen binding analysis, blood was drawn into 1/10 vol 3.8% sodium citrate. Blood was mixed with 5 mL of BSGC (pH, 7.3) and centrifuged at 200g for 10 minutes to prepare platelet-rich plasma. Platelet-rich plasma (1 mL) was passed through a 20 mL Sepharose 4B column equilibrated with BSGC (pH, 7.3), and the fraction containing platelets was collected. Platelets were counted on a Baker System 9000 cell counter and adjusted to 50,000/pL with BSGC.
Platelet activation was assessed in washed whole blood as previously d e~c r i b e d~,~ or by the following adaptation of those methods. A total of 20 pL of gel-filtered platelets was added to each of seven 15-mL polypropylene tubes containing 928 pL of BSGC (pH, 7.3) supplemented with 2 pL of G5-biotin (1 mg/mL) and 50 pL of various concentrations of diluted bovine thrombin in BSGC (pH, 7.3). The tubes were incubated in a 37°C water bath for 10 minutes, followed by the addition of 1 mL of 0.6% formaldehyde in PBS. The tubes were then incubated at room temperature (RT) for 20 minutes, followed by the addition of 10 mL BSGC (pH, 7.3) supplemented with 0.1% BSA and 2 mmoVL EDTA (BSGC-BSA), and centrifuged at 1,250g for 18 minutes at RT to remove the fixative. Pelleted cells were resuspended in 0.4 mL of BSGC (pH 7.3). A total of 200 pL of the resuspended cells was transferred to another tube, followed by the addition of 2 pg streptavidin-PE and 2 pg of In vivo protocol.
Geljiltration ofplatelets.
Assessment of platelet activation in response to thrombin.
FITC-2F9. After incubation at RT for 30 minutes, samples were washed with BSGC-BSA as described above. After resuspension in 0.5 mL BSGC-BSA, samples were analyzed by flow cytometry.
Assessment of activation of TO+ platelets in response to thrombin. To determine the thrombin-responsiveness of a subpopulation of platelets less than 24 hours old,17 thrombin dose-response curves were performed on gel-filtered platelets as detailed above, and the platelets were then labeled with the RNA-binding dye, TO. Specifically, after the thrombin activation, formalin-fixation, and wash steps described above, 200 pL of sample were incubated with 4 pL streptavidin-TRI-COLOR for 30 minutes at RT to label the biotinylated-G5 antibody. After incubation with 1 mL TO solution for 30 minutes at RT, samples were analyzed by flow cytometry as described below. Streptavidin-TRI-COLOR was used in these experiments, because its emission spectrum does not overlap significantly with that of Adenosine diphosphate (ADP)-induced jibrinogen binding. Fibrinogen binding to activated platelets was performed according to a modification of the method of Warkentin et aLZ2 A total of 400 pL of gel filtered dog platelets was mixed with 0.2 mL of citrated dog plasma and 1.2 mL of HEPES buffer (10 mmol/L HEPES, 145 mmoVL NaCI, 5 mmom KCI, 1 mmom MgSO, [pH, 7.41). A total of 180 pL of the mixture was added to each of seven wells of a 96-well plate, followed by the addition of 20 pL of various concentrations of ADP (final concentration, mol/L to lo-, mom), and was incubated for 40 seconds at RT. Next, 100 pL of the reaction mix were transferred to tubes containing 2 mL of 0.3% formaldehyde in PBS and fixed for 20 minutes. A total of 10 mL of BSGC-BSA was then added, and the tubes were centrifuged at 1,250g for 18 minutes. The pellets were resuspended in 0.2 mL of BSGC. A total of 5 pg of FITC-conjugated chicken antidog fibrinogen9 was added to each tube and allowed to incubate at RT for 30 minutes with occasional agitation, followed by washing in BSGC-BSA. The pellets were resuspended in 0.5 mL of BSGC, and the samples were analyzed by flow cytometry (settings: forward scatter [FSC], log EOO; side scatter [SSC], log 332; fluorescence 1 [FLI], log 520; FSC threshold, 260). In some experiments, gel-filtered platelets were first incubated with 100 ng/mL of active TPO or 100 ng/mL of heatinactivated TPO (100°C for 5 minutes) for 45 minutes at RT before the ADP-induced fibrinogen-binding study.
The percentage of platelets activated at the various concentrations of thrombin was determined with a FACScan flow cytometer (Becton Dickinson) according to previously described method^.^.^ A total of 10,OOO events were analyzed for Pselectin expression. For analysis of the thrombin dose-response characteristics of TO' platelets, the flow cytometer was set as follows: FSC, log Em; SSC, log 350; FLl, log 700; and FL3, log 500. A total of 50,000 total platelets were analyzed, and the percentage of TO' platelets within the activated ((359 and nonactivated populations was determined.
Dog plasma fibrinogen was measured by ELISA. Briefly, 96-well microtiter plates were coated with rabbit antihuman fibrinogen IgG at a dilution of 1 : 1,000 in carbonate buffer (pH, 9.6). After blocking, diluted samples and standards were applied to washed plates and bound fibrinogen was detected with biotinylated MoAb 2Bll (diluted 1:200) raised against dog fibrinogen. Bound antibody was detected by incubation with streptavidin-peroxidase. The plates were developed by addition of o-phenylenediamine dihydrochloride/H20, and the absorbance at 492 mp (OD492) measured after the reaction was stopped with 1 m o m H,S04.
The statistical significance of differences in means was tested with a two-tailed Student's t-test.
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RESULTS
To compare platelet function under circumstances in which platelet counts were not drastically
Platelet counts.
For different between treatment groups, a dose of TPO was used to promote elevations in platelet counts that would approximate or modestly exceed that expected with IL-6 (Fig 1) . After the administration of TPO (1 pgikg/d) or IL-6 (40 pg/ kg/d), platelet counts were monitored several times per week. For TPO-treated animals, a maximal increase of 115% above the pretreatment count was observed on days 11 to 13, whereas an increase of 72% above the pretreatment count occurred in IL-6-treated dogs at this same time. Although the increment in platelet count for the IL-6-treated dogs was less than that observed with TPO, the difference was not statistically significant ( P = .09).
In vitro responsiveness of platelets to thrombin stimulation. At various times during the course of cytokine administration, platelet responsiveness to graded doses of thrombin was determined by flow cytometry; results are reported as a thrombin ECsO, the effector concentration (EC) resulting in 50% a~tivation.~.' A summary of these EC50 values from five separate sets of animals is presented in Fig 2. As early as day 2, a decrease in the EC5,, for thrombin in IL-6-treated dogs was observed, although the decrease was not statistically significant until day 5 when the EC50 had dropped to 73.1% t-6.1% (mean t-1 SD; n = 5 ) of control ( P < .01).
By day 15, the thrombin ECso had returned to normal in the IL-6-treated animals; IL-6 administration was stopped on day 9. In contrast, there was no significant difference in the EC5o for thrombin between TPO-treated and control dogs at any time point. These data indicate that less thrombin is required to activate the platelets from IL-6-treated animals when compared with that for either TPO-treated or control animals. It is noteworthy that the change in ECso in IL-6-treated animals first occurred at day 5 when platelet counts for IL-6 and TPO animals were essentially identical (Fig 1) and before these platelet counts were significantly elevated above control levels ( P > .12).
IL-6 markedly augments plasma fibrinogen that might compete for thrombin and alter the thrombin dose-response curve in an unpredictable fashion. In contrast, TPO does not affect fibrinogen concentrations (mean, 1.28 ? 0.06 mg/mL; range, 1.03 to 1.57 mg/nL throughout the treatment course; n = 4). All of the experiments shown in Fig 2 were per- formed with plasma-depleted platelets, either by washing whole blood (one experiment) or by gel filtration (four experiments). No differences were noted with the two techniques. For example, in Fig 2, the IL-6 -treated animals at day 5 had a mean change in thrombin EC50 to 73.1% t-6.1% of control values when all samples were analyzed; if only the gel filtered samples are considered, the change was 74.9% 2 5.4%. Previous studies have shown that TO' platelets in the dog are less than 24 hours old.17 Before treatment, the mean percentage of TO+ platelets in all animals was 6.5% ? 0.8% (n = 15), and Fig 3A shows the percentage of TO+ platelets during cytokine administration. By day 3 to 4, a slight increase in TO+ platelets was observed in both the TPO-and IL-6-treated dogs followed by a modest decrease after cessation of the cytokine, although none of the changes were statistically significant. Figure 3B shows the absolute levels of TO' platelets during cytokine administration. TPO resulted in statistically significant elevations in TO+ platelet count on days Cytokine-induced production of TO+ platelets. control values on days 5 to 6,9, and 12 (P < .M). For IL-6, the elevation in absolute TO+ counts we. significantly above control only for day 9 (P < .MI. The difference between TPO and IL-6 was significant only for day 12 ( P < .05).
5:
5 to 6, 9, and 12 after initiation of the cytokine (P < .05);
IL-6 also produced increases in TO' platelet counts, although only the day-9 value is significantly different from control values. It is noteworthy that the increases in both the percentage of TO+ platelets (Fig 3A) , and the absolute numbers of TO' platelets ( Fig 3B) do not correlate well with the increase in total platelets (Fig 1) . Considering the dramatic increase in total platelet count elicited by these cytokines, large increases in the percentage of TO' platelets, in particular, would be e x p e~t e d . *~*~ The reason for this apparent discrepancy is not clear but may reflect either an inability of TO to detect all newly synthesized platelets or the difficulty of quantitating all TO+ platelets, because there is some overlap with TO-platelets during flow cytometric anal~sis.'~ Flow cytometric analysis permits an assessment during IL-6 and TPO administration of the thrombin responsiveness of the very young, TO+ subpopulation of platelets (Fig 4) . By day 5, the ECS0 for TO+ platelets in IL-6-treated dogs decreased to 46.5% ? 13.1% (mean ? 1 SD; n = 4) of control values (P < .001); after cessation of IL-6, EC50 values returned to normal. In TPO-treated dogs, no significant changes in thrombin EC5o values were observed. These divergent changes in the EC5o occurred despite the fact that there are no significant differences in either the percentage of TO+ platelets or the total platelet counts between the TPO-and IL-6-treated dogs for days 5 or 8 (Fig 1 and 3) . After discontinuation of TPO, TO+ platelets in these animals showed a trend of being less sensitive to thrombin with slightly inThrombin responsiveness of TO+ platelets.
creased EC5o values, although no statistically significant differences were observed. Effects of TPO on platelet responsiveness to thrombin and ADP in vitro. The above data show that IL-6 has a greater effect than TPO on platelet reactivity for the total platelet population and, in particular, for TO' platelets. Previous studies from our laboratory have suggested that the IL-6-induced alteration in platelet function in dogs is mediated via an effect of the cytokine on megakaryocytopoiesis rather than via a direct effect on platelets per se.' To determine if TPO has any direct effects on platelet responsiveness to thrombin or ADP, the hormone (100 ng/mL) was incubated with normal gel-filtered platelets for 45 minutes at RT, followed by performance of a thrombin dose-response study or an ADP-induced fibrinogen-binding study as described in 
DISCUSSION
Previous studies from our laboratory have indicated that administration of IL-6 leads to the production of platelets with increased reactivity to thrombin: suggesting that cytokines that augment thrombocytopoiesis quantitatively may also alter platelet function. Analogous effects on the granulocyte-macrophage lineage have been described, with granulo- cyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) having been shown to alter function of mature g r a n~l o c y t e s .~~.~~ The physiological mechanism for the IL-6-stimulated increase in platelet sensitivity to thrombin is unknown but may be caused by (1) stimulation of platelet production leading to an influx of young platelets into the circulation, (2) an alteration of the platelets that is unrelated to platelet age, and/or (3) both mechanisms. Earlier literature has suggested that young, newly produced platelets may be hyperfunctional27228; however, methodological considerations related to the capability of clearly distinguishing young from old platelets have not permitted definitive conclusions. Using biotinylation technology, we have shown recently that young canine platelets have an increased sensitivity to thrombin stimulation.' Nonetheless, the possibility existed that the functional changes induced by IL-6 were not entirely related to the influx of young platelets into the circulation. The availability of TPO, likely the physiological regulator of platelet product i~n , '~.~' . '~ has provided a novel means to evaluate platelet function under conditions of stimulated production, rendering it possible to experimentally determine if the effects of IL-6 on platelets are related primarily to increased thrombocytopoiesis.
In the present study, platelets from dogs treated with IL-6 or TPO were activated in vitro with graded doses of thrombin. The data show that the responsiveness of the total population to thrombin was greater in the IL-6-treated animals, despite the fact that platelet counts and the percentage of TO+ cells were similar or modestly higher in the TPO-treated dogs. Furthermore, when a direct analysis of thrombin reactivity of the TO+ platelets was performed in both groups, it was observed that the TO+ platelets in the TPO-treated dogs behaved similarly to TO+ platelets derived from normal animals, whereas the TO+ platelets from the IL-6-treated animals were substantially more reactive to thrombin.
These data suggest that IL-6 has an effect on platelet function that is clearly different from that of TPO. Although the molecular mechanism of this alteration is unknown, it is clear that platelet activation is a sensitive balance of inhibitory and activating pathway^,^' and the results presented herein suggest that these two arms of platelet homeostasis may be regulated differentially. In IL-6-driven platelets, it appears that the activation pathway predominates as indicated by the hypersensitivity of these TO' platelets relative to TO+ platelets from control or TPO-treated animals. Elucidation of the mechanisms regulating the expression of these putative pathways awaits further investigation.
The analysis of platelet activation in this study has focused on one marker of activation, P-selectin expression on the cell surface. Although P-selectin expression is a widely used indicator of 0-granule secretion, other possible activation markers of physiological significance include, but are not limited to, eicosanoid production and binding of various adhesive proteins." Although disagreement may exist as to the most relevant marker of platelet activation, the significance of a-granule secretion in platelet function is supported by the occurrence of bleeding disorders associated with abnormal a-granule f~nction.~'
The potential clinical significance of these findings are speculative at this time. TPO augments platelet production but does not alter function to a significant extent; these findings argue for the potential safety of this hormone when used for clinical purposes. In contrast, IL-6 appears to alter platelet function (at least in response to thrombin) in a manner disproportionate to the overall age of the population, raising the potential that pathological thrombosis might occur with this cytokine. Nevertheless, under conditions in which the platelet count is very low, bleeding is occurring, and the risk of thrombosis is not an issue, IL-6 might be capable of ameliorating bleeding precisely because of the increased reactivity of the platelets. Direct testing of these hypotheses in bleeding and thrombosis models will be required.
